Back to Journals » Cancer Management and Research » Volume 5

Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel

Authors Bensadoun RJ, Humbert P, Krutmann J, Luger T, Triller R, Rougier A, Seite S, Dreno B

Received 30 July 2013

Accepted for publication 7 October 2013

Published 9 December 2013 Volume 2013:5 Pages 401—408

DOI https://doi.org/10.2147/CMAR.S52256

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


René-Jean Bensadoun,1 Phillipe Humbert,2 Jean Krutman,3 Thomas Luger,4 Raoul Triller,5 André Rougier,6 Sophie Seite,6 Brigitte Dreno7

1Department of Radiation Oncology, CHU Poitiers, Poitiers Cedex, 2Department of Dermatology, University Hospital of Besançon, Besançon, France; 3IUF-Leibniz Research Institute for Environmental Medicine, Heinrich-Heine University, Düsseldorf, 4Department of Dermatology, University of Münster, Münster, Germany; 5Centre of Dermatology, Hertford British Hospital, Levallois-Perret, 6La Roche-Posay Laboratoire Pharmaceutique, Asnières, 7Department of Cancero-Dermatology, Hôtel Dieu, CHU Nantes, France

Abstract: Skin reactions due to radiotherapy and chemotherapy are a significant problem for an important number of cancer patients. While effective for treating cancer, they disturb cutaneous barrier function, causing a reaction soon after initiation of treatment that impacts patient quality of life. Managing these symptoms with cosmetics and nonpharmaceutical skin care products for camouflage or personal hygiene may be important for increasing patient self-esteem. However, inappropriate product choice or use could worsen side effects. Although recommendations exist for the pharmaceutical treatment of skin reactions, there are no recommendations for the choice or use of dermatologic skin care products for oncology patients. The present guidelines were developed by a board of European experts in dermatology and oncology to provide cancer care professionals with guidance for the appropriate use of non-pharmaceutical, dermocosmetic skin care management of cutaneous toxicities associated with radiotherapy and systemic chemotherapy, including epidermal growth factor inhibitors and monoclonal antibodies. The experts hope that these recommendations will improve the management of cutaneous side effects and hence quality of life for oncology patients.

Keywords: skin care, cosmetic, dermatological toxicity, folliculitis, xerosis, chemotherapy, radiotherapy, supportive care, cancer, consensus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]